Accordingly, HDAC6 inhibition with pharmacological agents represents an attractive therapeutic target for DMD offering many advantages including ease of administration, impact on all muscles and benefits to all patients regardless of the dystrophin mutations. The gene discussed is HDAC6; the disease is Duchenne muscular dystrophy.